Saxenda (liraglutide 3 mg) and Wegovy (semaglutide 2.4 mg) are both Novo Nordisk GLP-1 receptor agonist injections approved for chronic weight management. The key differences are frequency (Saxenda daily, Wegovy weekly), potency (Wegovy produces greater weight loss), and molecule (Saxenda is liraglutide, Wegovy is semaglutide). Most patients and clinicians prefer Wegovy for its weekly dosing and greater efficacy, but Saxenda remains an option when Wegovy is unavailable, not covered, or not tolerated.
Side-by-Side Comparison
| Feature | Saxenda | Wegovy |
|---|---|---|
| Generic name | Liraglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA indication | Chronic weight management (adults and ≥12 years) | Chronic weight management (adults and ≥12 years); CV risk reduction in obesity |
| Frequency | Daily SC injection | Weekly SC injection |
| Target dose | 3.0 mg daily | 2.4 mg weekly |
| Starting dose | 0.6 mg daily | 0.25 mg weekly |
| Titration schedule | Weekly +0.6 mg to 3.0 mg over 5 weeks | Monthly to 0.5, 1, 1.7, 2.4 mg over 16 weeks |
| Average weight loss | ~8% body weight (SCALE 56 weeks) | ~15% body weight (STEP 1, 68 weeks) |
| Pediatric approval | 2020 (≥12 years) | 2022 (≥12 years) |
| Approval year (adult) | 2014 | 2021 |
| Cardiovascular indication | No | Yes (SELECT trial) |
| List price/month | ~$1,350 | ~$1,350 |
What Each One Is
Saxenda (liraglutide 3 mg) is a once-daily subcutaneous injection FDA-approved in 2014 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. The same molecule is also marketed as Victoza at lower doses (up to 1.8 mg daily) for type 2 diabetes.
Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection FDA-approved in 2021 for chronic weight management. The same molecule is also marketed as Ozempic (lower doses, up to 2 mg weekly) for type 2 diabetes, and Rybelsus (oral) for type 2 diabetes. In 2024 Wegovy received additional FDA approval for reducing major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
Weight Loss Comparison
| Outcome | Saxenda (SCALE) | Wegovy (STEP 1) |
|---|---|---|
| Average body weight loss | 8.0% | 14.9% |
| Patients achieving ≥ 5% loss | 63% | 86% |
| Patients achieving ≥ 10% loss | 33% | 69% |
| Patients achieving ≥ 15% loss | 14% | 50% |
| Trial duration | 56 weeks | 68 weeks |
Wegovy produces approximately twice the weight loss of Saxenda. The SCALE trial of Saxenda showed substantial benefit relative to placebo (placebo loss ~2.6 percent), but semaglutide’s greater pharmacologic potency and longer half-life translate to larger and more durable weight reductions in STEP.
Mechanism Differences
- Both activate the GLP-1 receptor to slow gastric emptying, increase satiety, and reduce caloric intake
- Semaglutide has a longer half-life (about 1 week) versus liraglutide (about 13 hours) — enabling weekly versus daily dosing
- Semaglutide binds the GLP-1 receptor with higher affinity and crosses into the brain more readily, contributing to greater appetite reduction
- Liraglutide and semaglutide are both 97 percent homologous with native human GLP-1 but differ in fatty acid side chains
When to Choose Saxenda
- Wegovy is unavailable due to supply shortages
- Insurance covers Saxenda but not Wegovy
- Patient prefers daily dosing for predictability or to avoid weekly side effect cycles
- Patient cannot tolerate Wegovy’s slower titration and prefers the faster Saxenda escalation
- Moderate weight loss target (~8 percent body weight)
When to Choose Wegovy
- Greater weight loss desired (~15 percent body weight)
- Established cardiovascular disease — cardiovascular indication based on SELECT
- Preference for weekly injections over daily
- Insurance covers Wegovy
Side Effects (Both)
- Nausea — most common; peaks in first 4 weeks for Saxenda, after each dose increase for Wegovy
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Decreased appetite
- Fatigue, headache
- Injection site reactions
- Gallbladder issues (cholelithiasis, cholecystitis)
- Pancreatitis (rare)
- Hypoglycemia when used with sulfonylureas or insulin
- Acute kidney injury (dehydration-driven)
- Boxed warning for thyroid C-cell tumors — contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2
Pediatric Use
Both are approved for adolescents aged 12 and older with obesity (BMI ≥ 95th percentile for age and sex) when used as part of a comprehensive obesity treatment program. SCALE Teens (Saxenda) and STEP TEENS (Wegovy) both demonstrated significant weight reduction versus placebo, with Wegovy producing greater reductions. Pediatric obesity treatment guidelines from the AAP increasingly include pharmacotherapy in this age group.
Dosing Schedules
Saxenda titration — Week 1: 0.6 mg daily → Week 2: 1.2 mg → Week 3: 1.8 mg → Week 4: 2.4 mg → Week 5+: 3.0 mg daily
Wegovy titration — Weeks 1–4: 0.25 mg weekly → Weeks 5–8: 0.5 mg → Weeks 9–12: 1.0 mg → Weeks 13–16: 1.7 mg → Weeks 17+: 2.4 mg weekly
Cost and Coverage
Both Saxenda and Wegovy list at approximately $1,350 per month. Manufacturer savings programs can lower commercial copays. Many insurance plans exclude weight-loss medications under formal coverage exclusions, though Wegovy’s cardiovascular indication is opening some coverage for cardiac patients. Medicare Part D historically excluded both for obesity but is evolving.
Switching Between Them
Many patients switch from Saxenda to Wegovy for the weekly dosing and greater weight loss. The typical approach is to discontinue Saxenda and start Wegovy at 0.25 mg weekly the following week, titrating monthly. Patients fully tolerant of Saxenda 3 mg often skip the 0.25 mg starting dose under physician guidance, beginning at 0.5 mg.
Lifestyle Pairing
Both medications work best alongside reduced-calorie diet and increased physical activity. Read about diet for weight loss and how it intersects with prediabetes reversal.
The Bottom Line
Wegovy produces approximately twice the weight loss of Saxenda, uses weekly rather than daily injections, and has an established cardiovascular indication. Saxenda remains a viable option when Wegovy is unavailable, not covered, or not tolerated. Side effects are similar. Cost is similar. Both have pediatric approval for adolescents with obesity. For most adults seeking pharmacotherapy for weight management, Wegovy is the preferred GLP-1 option from Novo Nordisk; tirzepatide-based therapy (Zepbound) may produce greater weight loss still. Talk to your doctor about which fits your goals, your medical profile, and your insurance.
